Literature DB >> 30054146

Long term outcomes among adults post transcatheter atrial septal defect closure: Systematic review and meta-analysis.

Sami Alnasser1, Douglas Lee2, Peter C Austin3, Christopher Labos4, Mark Osten5, David T Lightfoot6, Shelby Kutty7, Ashish Shah8, Lukas Meier5, Lee Benson9, Eric Horlick10.   

Abstract

BACKGROUND: Transcatheter Closure (TC) has become the main stay therapy for many secundum atrial septal defects (ASD) based on short and intermediate term outcome data. Long-term safety and efficacy of this approach among adult patients however, is not well established. METHODS AND
RESULTS: A comprehensive search of major electronic databases for studies reporting the long-term (≥5 year) outcomes post TC among adults yielded 114 studies, 9 of which had met the inclusion criteria. This included 1015 patients with a mean age of 45 years ± 5.5 years, two third were female with a mean follow up duration 6.4 years ± 2.7 years. The weighted proportions of long-term mortality and stroke with 95% confidence intervals (CI) were 2.4% (95%CI 0.9%-6.1%) and 2.1% (95%CI 0.7%-5.7%) respectively. Atrial arrhythmia occurred in 6.5% (95%CI 3.5%-11.7%) and atrial fibrillation in 4.9% (95%CI 1.9%-11.7%). ASD related re-interventions were encountered in 2.3% (95%CI 1.0%-5.4%) and residual shunt in 4.2% (95% CI 1.3%-12.4%), with 1 case of suspected device erosion 0.9% (95%CI 0.4-2.2%). Frame fractures and late migrations were observed at 4.2% (95%CI 1.5%-11.5%) and 1.2% (95%CI 0.3%-4%) respectively. No cases of occluder endocarditis or thrombosis were reported. IN
CONCLUSION: This is the first study that systematically analyzes the long-term outcomes after TC providing important estimates for various clinical and occluder related outcomes. The analysis suggests preserved long-term safety post TC; however, this is limited due to the variable quality of available evidence and requires further assessment by larger studies with more comprehensive follow-up data.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Atrial septal defects; Long-term outcomes; Meta-analysis; Transcatheter approach

Mesh:

Year:  2018        PMID: 30054146     DOI: 10.1016/j.ijcard.2018.06.076

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Initial Clinical Experience with the Biodegradable AbsnowTM Device for Percutaneous Closure of Atrial Septal Defect: A 3-Year Follow-Up.

Authors:  Yifan Li; Yumei Xie; Boning Li; Zhaofeng Xie; Junjun Shen; Shushui Wang; Zhiwei Zhang
Journal:  J Interv Cardiol       Date:  2021-07-30       Impact factor: 2.279

Review 2.  2019 Chinese expert consensus statement on left atrial appendage closure in patients with atrial fibrillation.

Authors:  He Ben; Ma Changsheng; Wu Shulin
Journal:  Pacing Clin Electrophysiol       Date:  2022-03-18       Impact factor: 1.912

3.  Transcatheter Closure of Atrial Septal Defect in Children: Single-Center Experience, Mid-Term Follow-up Results.

Authors:  Yeşfa Şebnem Özbay; Rukiye Eker; Aygün Dindar; Ümrah Aydoğan; Kemal Nişli
Journal:  Turk Arch Pediatr       Date:  2022-07

4.  Initial experiences with a novel biodegradable device for percutaneous closure of atrial septal defects: From preclinical study to first-in-human experience.

Authors:  Yi-Fan Li; Yu-Mei Xie; Jun Chen; Bo-Ning Li; Zhao-Feng Xie; Shu-Shui Wang; Zhi-Wei Zhang
Journal:  Catheter Cardiovasc Interv       Date:  2019-11-12       Impact factor: 2.692

5.  Key Regulatory Differentially Expressed Genes in the Blood of Atrial Septal Defect Children Treated With Occlusion Devices.

Authors:  Bo-Ning Li; Quan-Dong Tang; Yan-Lian Tan; Liang Yan; Ling Sun; Wei-Bing Guo; Ming-Yang Qian; Allen Chen; Ying-Jun Luo; Zhou-Xia Zheng; Zhi-Wei Zhang; Hong-Ling Jia; Cong Liu
Journal:  Front Genet       Date:  2021-12-08       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.